DrBernhardHertelBernhardHertel博士Muni慕尼黑Ger.pptVIP

* In the economic society it is well known that a market-value is always the most reliable and robust value for every kind of asset. It shows what the buyer is willing to pay for the asset and what the seller wants to receive at the same time. So the general idea is to find a similar patent that has already been priced and traded. The actual value/price is differentiated out of historical transactions. But with this approach there are two major problems: First it is not that easy to gather data of patents which are already priced and traded. Second every Patent is unique and only a few are at least a little similar. Source: IBP GmbH Web * * * * * * * * * * * * * * * * * * * * * * * * * * * China November 2008 Dr. Bernhard Hertel, Munich Germany * The scientific founders of Alnylam Pharmaceuticals are among the worlds leaders in RNA research and in RNA interference in particular: * Phillip Sharp - MIT Center for Cancer Research; Director, McGovern Institute for Brain Research; Nobel Laureate; founder of Biogen; National Academy of Sciences. * Paul Schimmel - Scripps Institute; founder of Alkermes, Repligen, Cubist Pharmaceuticals; National Academy of Sciences (not on photo). * David Bartel - Whitehead Institute, MIT. * Thomas Tuschl - Laboratory of RNA Molecular Biology, Rockefeller University. * Phillip Zamore - Department of Biochemistry Molecular Pharmacology, University of Massachusetts Medical School The other founders bring a range of experience in the biotechnology industry: * Christoph Westphal - Start-up CEO of Alnylam Pharmaceuticals; General Partner, Polaris Venture Partners; founder/CEO of Mimeon * John Clarke - Managing General Partner, Cardinal Partners; founder/CEO of Alkermes and Cubist Pharmaceuticals. * John Conley - Ten years experience with Biogen, most recently as Treasurer and board member of Genovo; former Manager, Bain and Company. Alnylam Pharmacueticals IncAlnylam医药公司 China November 2008 Dr. Bernhard